Compliance Investigations & White Collar


Ullman Quoted in Article on Warning Letters to Amazon
September 16, 2022 | Compliance Investigations & White Collar | Health Services

Marc Ullman was quoted in the NutraIngredientsUSA article, “Amazon warning over skin tag products puts online giant on notice for assuring regulatory compliance.”

The article explains that the FDA issued a warning letter to Amazon for two marketers whose products are sold on Amazon’s site. These products claim to remove skin tags, but are not

Read More
Ullman Moderates Panel on Regulation and Litigation in US Supplement Market
August 24, 2022 | Compliance Investigations & White Collar

As part of SupplySide West 2022, Marc Ullman will moderate a panel entitled “State of dietary supplement regulations and litigation: 2022 update.”

The session, which takes place November 3, 2022, will cover:

  • Mandatory product listing and broader reform of the Dietary Supplement Health and Education Act of 1994 (DSHEA)
  • NAC, CBD and other ingredients
Read More
Ullman Comments on “Compliance responsibilities when using a contract manufacturer”
August 8, 2022 | Compliance Investigations & White Collar

Marc Ullman spoke with Natural Products INSIDER for the article, “Compliance responsibilities when using a contract manufacturer.”

Some brands contract out their products to individual manufacturers. During this collaboration, many questions can arise regarding compliance responsibility and reporting regulations.

There are a multitude of manufacturing and reporting requirements, such as cGMPs (current good manufacturing practices), FSMA

Read More
Lunch & Learn Series: New OMIG Compliance Regulations: What You Need to Know
July 12, 2022 | Compliance Investigations & White Collar | Health Services

On July 13, the Office of Medicaid Inspector General (OMIG) published proposed regulations implementing 2020 changes to law relating to provider compliance programs, Medicaid managed care fraud, waste and abuse prevention programs, and OMIG’s self-disclosure program. The proposed changes will significantly impact both payers and providers alike.

Hear from Robert Hussar, a compliance professional and

Read More
Kaiser a PLI Panelist on Drug and Device Enforcement Trends
July 6, 2022 | Compliance Investigations & White Collar | Health Services

On September 28, 2022, Jeff Kaiser will be a panelist at the Practising Law Institute’s program, Life Sciences 2022: Navigating Legal Challenges in Drug and Device Industries. The program is designed for attorneys and allied professionals who counsel pharmaceutical and life sciences companies.

Entitled “Enforcement Trends Impacting the Drug and Device Industries,” Jeff’s panel will

Read More
Ullman Reacts to FDA’s Amnesty for NDIN Non-Filers
June 10, 2022 | Compliance Investigations & White Collar

Marc Ullman spoke with Natural Products INSIDER for the article, “FDA hoping to shrink pool of noncompliant ingredient notifications.”

The story discusses the U.S. Food & Drug Administration’s recent guidance that it is providing a 180-day amnesty to manufacturers of nutritional products that failed to file a New Dietary Ingredient (NDI) notification.

Marc is not convinced

Read More
Ullman Cited in Missing NDI Filings Article
June 8, 2022 | Compliance Investigations & White Collar

Marc Ullman was cited in the NutraIngredientsUSA article, “FDA announces enforcement discretion amnesty window on missing NDI filings.”

The article explains the FDA’s announcement that it will exercise enforcement discretion on missing New Dietary Ingredient Notifications.

Ullman stated that the announcement has less impact than it should.

“When that window closes, what are they going

Read More
NDI warning letters fuel criticism of FDA enforcement approach—again
June 2, 2022 | Compliance Investigations & White Collar

Marc Ullman was cited in the Natural Products Insider article “NDI warning letters fuel criticism of FDA enforcement approach—again.”

In May, the FDA issued warnings to several companies who sell dietary supplements. The warning letters indicated that some of the supplements “could potentially harm consumers,” according to a constituent update. Targeting six supplements specifically, the

Read More
Ullman Expresses Suspicion of FDA Warning Letters
May 10, 2022 | Compliance Investigations & White Collar

Marc Ullman, quoted in the NutraIngredients-USA article, “FDA cites 10 firms for use of ingredients flagged as illegal,” expressed his suspicion of the recent warning letters that the FDA sent to 10 dietary supplement companies using ingredients that have been added to its Ingredients Advisory List.

The FDA has marked some of these potentially harmful

Read More
Ullman Comments on Future Results of FDA Policy on NAC
April 29, 2022 | Compliance Investigations & White Collar

Marc Ullman commented on how the FDA’s recent enforcement discretion of NAC will bring some certainty to the market in NutraIngredientsUSA article, “Enforcement discretion gives some solace to NAC space, observers say.”

Ullman stated, “FDA enforcement discretion on matters like NAC should be fairly reliable in the absence of any data emerging indicating a potential

Read More
Next Page

Get legal updates and news delivered to your inbox